Skip to main content
. 2022 Mar 22;39(5):2222–2235. doi: 10.1007/s12325-022-02078-5

Table 2.

Crude incidence rate per 100,000 person-years and prevalencea per 100,000 persons of SSc and SSc-ILD (95% CI) by age groups and sex (JMDC)

Sex SSc SSc-ILD
Overall < 65 years ≥ 65 years Overall < 65 years ≥ 65 years
Incidence rates per 100,000 person-years (95% CI)
 Population at risk, n M 3,749,068 3,669,882 79,186 3,746,204 3,667,536 78,668
F 3,132,353 3,058,146 74,207 3,129,888 3,055,999 73,889
All 6,881,421 6,728,028 153,393 6,876,092 6,723,535 152,557
 Incident events, nb M 204 175 29 54 45 9
F 729 668 61 207 185 22
All 933 843 90 261 230 31
 Person-years at risk, total M 7,896,552 7,762,000 134,553 7,890,285 7,756,632 133,653
F 6,197,567 6,074,213 123,354 6,193,081 6,070,250 122,832
All 14,094,119 13,836,212 257,907 14,083,366 13,826,882 256,484
 Crude incidence rate per 100,000 person-years (95% CI) M 2.6 2.3 21.6 0.7 0.6 6.7
(2.3–3.0) (1.9–2.6) (15.0–31.0) (0.6–0.9) (0.4–0.8) (3.6–12.8)
F 11.8 11.0 49.5 3.3 3.1 17.9
(10.9–12.7) (10.2–11.9) (38.5–63.5) (2.9–3.8) (2.6–3.5) (11.9–27.1)
All 6.6 6.1 34.9 1.9 1.7 12.1
(6.2–7.1) (5.7–6.5) (28.4–42.9) (1.6–2.1) (1.5–1.9) (8.5–17.2)
Prevalence of SSc and SSc-ILD per 100,000 persons (95% CI)
 Population at risk, n M 3,749,261 3,670,063 79,198 3,749,261 3,670,069 79,192
F 3,133,274 3,058,935 74,339 3,133,274 3,058,956 74,318
All 6,882,535 6,728,998 153,537 6,882,535 6,729,025 153,510
 Prevalent events, nc M 446 399 47 170 152 18
F 2102 1858 244 787 679 108
All 2548 2257 291 957 831 126
 Crude prevalence rate per 100,000 persons (95% CI) M 11.9 10.9 59.3 4.5 4.1 22.7
(10.8–13.1) (9.8–12.0) (43.6–78.9) (3.9–5.3) (3.5–4.9) (13.5–35.9)
F 67.1 60.7 328.2 25.1 22.2 145.3
(64.3–70.0) (58.0–63.6) (288.4–372.0) (23.4–26.9) (20.6–23.9) (119.2–175.4)
All 37.0 33.5 189.5 13.9 12.4 82.1
(35.6–38.5) (32.2–35.0) (168.4–212.6) (13.0–14.8) (11.5–13.2) (68.4–97.7)

CI confidence interval, F female, JMDC Japanese Medical Data Centre, M male, SSc systemic sclerosis, SSc-ILD SSc-associated interstitial lung disease

aPrevalence was calculated by including prevalent and incident cases of SSc and SSc-ILD

bThe total number of patients with a new diagnosis of SSc or SSc-ILD identified during the entire patient selection period for the overall incidence rate (1 September 2016 to 31 August 2019)

cThe total number of patients with a diagnosis of SSc or SSc-ILD identified anytime during the patient selection period, for the overall prevalence (1 September 2016 to 31 August 2019)